Paul F. Lizzul - Jan 3, 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Chief Medical Officer
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Stock symbol
ANAB
Transactions as of
Jan 3, 2024
Transactions value $
$0
Form type
4
Date filed
1/5/2024, 05:00 PM
Previous filing
Sep 18, 2023
Next filing
Jan 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Stock Option (right to buy) Award $0 +116K $0.00 116K Jan 3, 2024 Common Stock 116K $21.19 Direct F1
transaction ANAB Restricted Stock Unit Award $0 +42.2K $0.00 42.2K Jan 3, 2024 Common Stock 42.2K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3 The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.